Vaxcyte

Nasdaq: PCVX · SEC EDGAR filings

Results on file1
Average 24h move+29.23%across 1 result with a complete 24h price
1 resultVaxcyte
Met endpoint

VAX-31

Phase 3 n=4,049 Pneumococcal Disease

Vaxcyte PCVX

24h stock move +29.23%

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.